其 他 安 全 警 示
|
| |
| Canada: Plavix: New recommendations for use with PPIs (English Only) |
| |
Health Canada informs health professionals and patients of updated recommendations involving the use of Plavix in combination with a class of drugs known as proton pump inhibitors (PPIs). New evidence has shown that while PPIs do interact with Plavix, not all reduce the effectiveness of Plavix to the same degree. The labelling for Plavix has been updated with new recommendations regarding the use of PPIs:
PPIs known to strongly or moderately reduce Plavix effectiveness should be avoided. Omeprazole is one of these.
If a PPI must be used in a patient taking Plavix, consider a PPI that does not interact as strongly. Pantoprazole is one of these.
Please refer to the following website in Health Canada for details:
http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_125-eng.php
In Hong Kong, Plavix and other products containing clopidogrel are available in Hong Kong and all are prescription drugs. Plavix is registered by Sanofi-Aventis Hong Kong Limited, and its package insert had already mentioned the drug interaction with PPIs. As regard to the new recommendations of Health Canada, the issue will be considered in the upcoming meeting of the Registration Committee of Pharmacy and Poisons Board.
Ends/ Friday, September 23, 2011
Issued at HKT 15:30
|
| |
|
